A
Aldeyra Therapeutics, Inc. (ALDX)
NCM – Real Time Price. Currency in USD
1.83
+0.03 (1.67%)
At close: Jun 26, 2026, 4:00 PM EDT
1.82
-0.01 (-0.28%)
After-hours: Jun 26, 2026, 6:29 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.83
+0.03 (1.67%)
At close: Jun 26, 2026, 4:00 PM EDT
1.82
-0.01 (-0.28%)
After-hours: Jun 26, 2026, 6:29 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $65.0M significantly exceed its total debt $15.5M, ensuring strong financial flexibility
Total current assets $65.4M exceed Total current liabilities $24.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.4) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-7.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$5.1M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.69 | 6.05 | 10 | |
| Quick ratio | 2.69 | 5.63 | 10 | |
| Debt to Equity | 0.37 | 0.30 | 7.0 | |
| Debt to Assets | 0.23 | 1.04 | 7.0 | |
| Interest coverage | -7.57 | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -259K | -263K | -250K | -252K | -258K |
| Operating Income | -63M | -43M | -60M | -35M | -28M |
| Net Income | -62M | -38M | -56M | -34M | -27M |
| EBITDA | -62M | -43M | -60M | -35M | -28M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 34.38 | 5.5 |
| Next quarter | N/A | 19.23 | 5.0 |
| Current year | N/A | 27.68 | 5.5 |
| Next year | -48.44 | 48.97 | 5.5 |
| Weighted average score | 5.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 46.57 | 45.45 | 3.57 | 8.5 |
| Y/Y | 999 | 65.23 | 64.71 | 59.02 | 10 |
| 3y average | 999 | 10.04 | 11.06 | 8.94 | 7.5 |
| 5y average | 999 | -6.2 | 7.54 | -3.94 | 4.5 |
| Weighted average score | 7.6 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |